Search

Displaying results 2711 - 2720 of 10000 in total
  1. Drug

    rdESAT-6

    go.drugbank.com/drugs/DB21906
    Approved

    rdESAT-6 is a recombinant dimer of _Mycobacterium tuberculosis_ early secretory antigenic target used as an ingredient in the diagnostic agent SIILTIBCY along with [rCFP-10].[L53638]

  2. Drug

    Lepirudin

    go.drugbank.com/drugs/DB00001
    ApprovedWithdrawn

    [L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. … [A246609] Lepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications.

  3. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset … Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors.

    Categories: Purinergic P2 Receptor Antagonists, Purinergic P2Y Receptor Antagonists
  4. Drug

    Remtolumab

    go.drugbank.com/drugs/DB15128
    Investigational

    Remtolumab is under investigation in clinical trial NCT02433340 (Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12

  5. Drug

    MVR-C5252

    go.drugbank.com/drugs/DB30379
    Investigational

    MVR-C5252 is a biologic drug. MVR-C5252 is under investigation in clinical trial NCT06126744 (Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252).

  6. Target

    Low affinity immunoglobulin gamma Fc region receptor III-B

    go.drugbank.com/bio_entities/BE0000901
    TargetHumans

    Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG.

    Polypeptides: Low affinity immunoglobulin gamma Fc region receptor III-BSynonyms: IgG Fc receptor III-1
  7. Target

    Low affinity immunoglobulin gamma Fc region receptor II-b

    go.drugbank.com/bio_entities/BE0002099
    TargetHumans

    Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. … Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor.

    Polypeptides: Low affinity immunoglobulin gamma Fc region receptor II-bSynonyms: IgG Fc receptor II-b
  8. Target

    Transient receptor potential cation channel subfamily V member 6

    go.drugbank.com/bio_entities/BE0005102
    TransporterTargetHumans

    Calcium selective cation channel that mediates Ca(2+) uptake in various tissues, including the intestine (PubMed:11097838, PubMed:11248124, PubMed:11278579, PubMed:15184369, PubMed:23612980, PubMed:29258289). Important for normal Ca(2+) ...

    Polypeptides: Transient receptor potential cation channel subfamily V member 6
  9. Target

    Transient receptor potential cation channel subfamily M member 5

    go.drugbank.com/bio_entities/BE0020643
    TargetHumans

    Monovalent cation-selective ion channel activated by intracellular Ca(2+) in a voltage- and temperature-dependent manner (PubMed:14634208). Mediates the transport of Na(+), K(+) and Cs(+) ions equally well (PubMed:14634208). Activated di...

    Polypeptides: Transient receptor potential cation channel subfamily M member 5Synonyms: Long transient receptor potential channel 5
  10. Drug

    Vemurafenib

    go.drugbank.com/drugs/DB08881
    ApprovedInvestigational

    Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E.[A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF. … After approval, Roche in collaboration with Genentech launched a broad development program. [L1012]